🔗 Share this article

As the US continues making sweeping revisions to its vaccination guidelines, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on coronavirus shots throughout the global health crisis and has focused upon alleged deaths following Covid vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Program

Public health authorities planned to unveil radical changes to the childhood vaccine schedule recently, aligning the US with Denmark’s national calendar, sources say – a major change that would put the US at odds with many the international standard with little proof for improved outcomes. The announcement has been delayed until the new year.

In place of the director of the vaccine center, Høeg is listed to speak at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for halting certain pediatric shot schedules in the US to become more similar to Denmark, a society with nationalized medicine and a number of inhabitants approximately the population of Wisconsin’s.

To date statements, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Background

Høeg has little discernible experience in drug development, approval processes or leadership, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a major agency. She is not an expert in drug approvals.”

Past commissioners of the center would “grasp legal statutes and the science of medication creation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who headed CBER have had.”

CDER has an vast workload at the agency, Woodcock pointed out.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and all of those must be looked after,” Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major leadership aspect to the role, which supervises more than 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Controversial Policies

In response to concerns about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “inquiries are based on incorrect assumptions”.

“This background is consistent with the duties of her role,” the official explained, citing the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a contentious one-day drug-approval program that allegedly troubled her former heads. “How are these medications being chosen for this fast-track system? Who takes the choices?” Dr. Howard asked. “There’s a lot of confidentiality going on at the agency right now.”

Broadly speaking, he said, “the FDA seems to be moving towards laxer regulations of all drugs, with the exception of shots.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, track record, some experts observe. She published a study using unconfirmed volunteer-provided data to determine the incidence of myocarditis after COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new federal leadership featured altering guidelines for novel immunizations and ending “unnecessary” immunizations, she stated after the election on a online show. At the FDA, Høeg has reportedly floated the idea of preventing teenage boys from getting COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her beliefs and reverse-engineers to accommodate the science in a very disingenuous, dishonest way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|